Dendreon Corporation news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

DNDNQ 0.0325
price chart
Dendreon, Maker of Prostate Cancer Drug Provenge, Files for Bankruptcy
An employee of Dendreon works on the company's prostate cancer drug Provenge.Credit Dendreon Corporation, via Associated Press.
Dendreon to Pursue Sale or Reorganization in Bankruptcy  Wall Street Journal
Related articles »  
Stock to Watch Dendreon Corporation (OTCMKTS:DNDNQ)
Dendreon Corporation (OTCMKTS:DNDNQ) continues to be highly volatile in recent days after the Company announced a strong Commercial Start to 2015.
Dendreon Gets Nod For Ch. 11 Liquidation Plan
Law360, Wilmington (June 2, 2015, 6:46 PM EDT) -- A Delaware bankruptcy judge on Tuesday blessed Dendreon Corp.'s proposed Chapter 11 plan, allowing the cancer treatment developer to dole out remaining proceeds from its $495 million sale to ...
Waiting for Reversal: Dendreon Corporation (OTCMKTS:DNDNQ)
Dendreon Corporation (OTCMKTS:DNDNQ) is steadily dropping lower on accelerating volume in recent days. The stock was recently de listed from the NASDAQ where it was trading over $50 a share in 2010.
Cancer Immunotherapy Companies: Looking Forward and Looking Back  Xconomy
Dendreon's Provenge Revenue Trends
Provenge seems to be in a run rate of $320 million per year, which would be a pretty successful drug if its cost of production were more normal and if it was one of many therapies of a corporation. But at $320 million per year it makes Dendreon a money ...
Is It Time To Give Up On Dendreon?
What happened to Seattle, Washington-based Dendreon Corporation (NASDAQ:DNDN)? There was once so much optimism and excitement about this biotechnology company pioneering active cellular immunotherapy (ACI) technology to develop drugs that ...
Related articles »  
Investors Are in Love With Dendreon Corporation
While spending 51% of the sales price to make the drug is better than the 69% it spent in the third quarter, but it's still 51%!
Sipuleucel-T Soon Available to Patients in Europe and Beyond  OncLive
Related articles »  
Dendreon Gets OK For Sweetened $495M Sale To Valeant
Law360, Wilmington (February 20, 2015, 4:33 PM EST) -- A Delaware bankruptcy judge gave the nod Friday to Dendreon Corp.'s sale to a unit of Valeant Pharmaceuticals International Inc., approving a sweetened deal that increased the purchase price from ...
What Does Dendreon Corporation's Fourth Quarter Mean For Investors?
Dendreon's (NASDAQ:DNDN) Provenge continues to be hotly debated among investors. The drug, which harnesses the immune system as a cancer-fighting weapon, is used to treat patients suffering from metastatic castration resistant prostate cancer, ...
Related articles »  
Dendreon's Plunge: No Short-Selling Conspiracy After All
Dendreon (NASDAQ:DNDN) shares have been absolutely decimated in the past month, with shares falling almost 75% from $40 at this point last month to $10.37 as of this writing.